FDA Approved: RISPERDAL CONSTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved Janssen's supplemental application for RISPERDAL CONSTA, a long-acting injectable antipsychotic (paliperidone palmitate).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Risperdal Consta (risperidone long-acting injectable)

Snippet

SUPPL AP for RISPERDAL CONSTA (RISPERIDONE)